Consolidating firms can't forget technologyAny vendor participating in the PACS market knows that it is being reshaped by the forces of consolidation. Driven by the desire to maximize distribution channels or to provide the right product mix to
Any vendor participating in the PACS market knows that it is being reshaped by the forces of consolidation. Driven by the desire to maximize distribution channels or to provide the right product mix to customers, Kodak and Imation, Medasys and Citation, and HBO and Imnet have decided in the last month to tie their respective companies' futures together.
Whether their strategies will prove successful is, of course, too early to tell. But with customers increasingly searching for complete, one-stop shopping for their PACS and healthcare-information technology needs, consolidation moves can only benefit these companies as they strive for a more prominent market presence.
Despite many valiant efforts, only a few small firms have been able to carve out a lasting niche for themselves in PACS. The rest have either been acquired by larger companies seeking to fill out their product line, or have simply exited the business for greener pastures.
Although the marketing message of these mergers and acquisitions can be powerful, ultimately it is the success these companies achieve in integrating their technologies that will dictate their fates. The history of the PACS market is replete with corporate marriages that failed to live up to the promises proclaimed in their press releases. As several vendors in this sector have found, slick advertising and marketing campaigns won't amount to much if the corresponding products fail to measure up to customer expectations. It's a lesson that has often been forgotten in the PACS market.
-Erik L. Ridley, Editor
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.